azelastine has been researched along with Allergic Conjunctivitis in 26 studies
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and safety of topical azelastine with topical mitomycin C (MMC) in patients with allergic conjunctivitis." | 9.10 | Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis. ( Pandey, RM; Ratan, SK; Sodhi, PK, 2003) |
| "Azelastine (AZE) in a novel, eye drop, formulation, was compared with topically applied sodium cromoglycate (SCG) and placebo (PLA) in the treatment of seasonal allergic conjunctivitis or rhino-conjunctivitis in a multicentre, parallel group study." | 9.10 | Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. ( Campbell, LM; Ellers-Lenz, B; Fell, PJ; Harrison, JM; James, IG; Petzold, U, 2003) |
| "The trial evaluated the effectiveness of the investigational antihistaminic and antiallergic compound Azelastine Eye Drops (AZE) in the treatment of allergic conjunctivitis using an allergen challenge model." | 9.09 | Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. ( Friedlaender, MH; Harris, J; LaVallee, N; Russell, H; Shilstone, J, 2000) |
| "05% levocabastine eye drops (103 patients) and in a double-blind manner with placebo (103 patients) during a 14-day treatment period involving patients with seasonal allergic conjunctivitis." | 9.09 | Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. ( Ellers-Lenz, B; Giede, C; Metzenauer, P; Petzold, U, 2000) |
| "05% azelastine eye drops twice daily administered for 14 days to patients with seasonal allergic conjunctivitis or rhinoconjunctivitis." | 9.08 | Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. ( Lenhard, G; Mivsek-Music, E; Obtulowicz, K; Perrin-Fayolle, M; Secchi, A, 1997) |
| "In a randomised, multicentre study, the effect of azelastine eye drops (n = 51 patients) was compared in a double-blind manner with placebo eye drops (n = 30 patients) and in an open manner with levocabastine eye drops (n = 32 patients) during a 14-day treatment period involving 113 children (aged 4 to 12 years) suffering from seasonal allergic conjunctivitis/rhinoconjunctivitis." | 9.08 | Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. ( Marzetto, M; Sabbah, A, 1998) |
| "05% azelastine eye-drops in patients with seasonal allergic conjunctivitis of > or = 1 year's duration." | 9.08 | Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. ( Giede-Tuch, C; Westhoff, M; Zarth, A, 1998) |
| "Azelastine is a selective H(1)-receptor antagonist that inhibits histamine release and interferes with activation of several other mediators of allergic inflammation." | 6.71 | Topical azelastine in perennial allergic conjunctivitis. ( Canonica, GW; Ciprandi, G; Ellers-Lenz, B; Hermann, R; Kolb, C; Petzold, U, 2003) |
| "The aim of this study was to compare short-term (5-minute) ocular comfort and drying effects of 3 topical antihistamine/mast cell stabilizers-epinastine, azelastine, and ketotifen-in patients with allergic conjunctivitis (AC)." | 5.13 | Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. ( Gomes, P; Ousler, GW; Torkildsen, GL, 2008) |
| "To compare the efficacy and safety of topical azelastine with topical mitomycin C (MMC) in patients with allergic conjunctivitis." | 5.10 | Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis. ( Pandey, RM; Ratan, SK; Sodhi, PK, 2003) |
| "Azelastine (AZE) in a novel, eye drop, formulation, was compared with topically applied sodium cromoglycate (SCG) and placebo (PLA) in the treatment of seasonal allergic conjunctivitis or rhino-conjunctivitis in a multicentre, parallel group study." | 5.10 | Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. ( Campbell, LM; Ellers-Lenz, B; Fell, PJ; Harrison, JM; James, IG; Petzold, U, 2003) |
| "The trial evaluated the effectiveness of the investigational antihistaminic and antiallergic compound Azelastine Eye Drops (AZE) in the treatment of allergic conjunctivitis using an allergen challenge model." | 5.09 | Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. ( Friedlaender, MH; Harris, J; LaVallee, N; Russell, H; Shilstone, J, 2000) |
| "05% levocabastine eye drops (103 patients) and in a double-blind manner with placebo (103 patients) during a 14-day treatment period involving patients with seasonal allergic conjunctivitis." | 5.09 | Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. ( Ellers-Lenz, B; Giede, C; Metzenauer, P; Petzold, U, 2000) |
| " Subjects with a history of allergic conjunctivitis who responded to the CAC at screening visits 1 and 2 were randomized to 1 of 3 treatment groups: olopatadine in 1 eye and azelastine in the other eye; olopatadine in 1 eye and placebo in the other eye; or azelastine in 1 eye and placebo in the other eye." | 5.09 | Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. ( Bensch, G; Berdy, GJ; Spangler, DL, 2001) |
| "05% azelastine eye drops twice daily administered for 14 days to patients with seasonal allergic conjunctivitis or rhinoconjunctivitis." | 5.08 | Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. ( Lenhard, G; Mivsek-Music, E; Obtulowicz, K; Perrin-Fayolle, M; Secchi, A, 1997) |
| "In a randomised, multicentre study, the effect of azelastine eye drops (n = 51 patients) was compared in a double-blind manner with placebo eye drops (n = 30 patients) and in an open manner with levocabastine eye drops (n = 32 patients) during a 14-day treatment period involving 113 children (aged 4 to 12 years) suffering from seasonal allergic conjunctivitis/rhinoconjunctivitis." | 5.08 | Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. ( Marzetto, M; Sabbah, A, 1998) |
| "05% azelastine eye-drops in patients with seasonal allergic conjunctivitis of > or = 1 year's duration." | 5.08 | Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. ( Giede-Tuch, C; Westhoff, M; Zarth, A, 1998) |
| "Olopatadine, an antihistamine used in allergic conjunctivitis, is under development as a nasal preparation for the treatment of allergic rhinitis." | 2.73 | The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. ( Costantini, C; Drake, M; Pipkorn, P; Proud, D; Reynolds, C; Sanico, A; Togias, A; Wall, M, 2008) |
| "Azelastine is a selective H(1)-receptor antagonist that inhibits histamine release and interferes with activation of several other mediators of allergic inflammation." | 2.71 | Topical azelastine in perennial allergic conjunctivitis. ( Canonica, GW; Ciprandi, G; Ellers-Lenz, B; Hermann, R; Kolb, C; Petzold, U, 2003) |
| "Azelastine is a selective H1-receptor antagonist, which has previously been demonstrated to be effective in the treatment of allergic rhinitis." | 2.68 | Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. ( Bagnasco, M; Buscaglia, S; Canonica, GW; Catrullo, A; Ciprandi, G; Fiorino, N; Montagna, P; Pesce, G, 1997) |
| " Newer topical medications are being used that have multiple actions, such as an antihistaminic effect coupled with mast-cell stabilisation, and which require reduced daily dosing due to their longer duration of action." | 2.43 | Pharmacotherapy of allergic eye disease. ( Flynn, TH; Larkin, F; Manzouri, B; Ono, SJ; Wyse, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 17 (65.38) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Eli, H | 1 |
| Solomon, A | 1 |
| Pipkorn, P | 1 |
| Costantini, C | 1 |
| Reynolds, C | 1 |
| Wall, M | 1 |
| Drake, M | 1 |
| Sanico, A | 1 |
| Proud, D | 1 |
| Togias, A | 1 |
| Torkildsen, GL | 1 |
| Ousler, GW | 1 |
| Gomes, P | 1 |
| Lambiase, A | 1 |
| Micera, A | 1 |
| Bonini, S | 1 |
| Shinde, UA | 1 |
| Shete, JN | 1 |
| Nair, HA | 1 |
| Singh, KH | 1 |
| Haicl, P | 2 |
| Cerná, H | 2 |
| Sodhi, PK | 1 |
| Pandey, RM | 1 |
| Ratan, SK | 1 |
| Nazarov, O | 1 |
| Petzold, U | 4 |
| Haase, H | 1 |
| Nguyen, DT | 1 |
| Ellers-Lenz, B | 4 |
| Hermann, R | 2 |
| Ciprandi, G | 3 |
| Cosentino, C | 1 |
| Milanese, M | 1 |
| Tosca, MA | 1 |
| James, IG | 1 |
| Campbell, LM | 1 |
| Harrison, JM | 1 |
| Fell, PJ | 1 |
| Canonica, GW | 2 |
| Kolb, C | 1 |
| Bielory, L | 1 |
| Buddiga, P | 1 |
| Bigelson, S | 1 |
| Manzouri, B | 1 |
| Flynn, TH | 1 |
| Larkin, F | 1 |
| Ono, SJ | 1 |
| Wyse, R | 1 |
| Sanchis-Merino, ME | 1 |
| Montero, JA | 1 |
| Ruiz-Moreno, JM | 1 |
| Rodriguez, AE | 1 |
| Pastor, S | 1 |
| Buscaglia, S | 1 |
| Catrullo, A | 1 |
| Pesce, G | 1 |
| Fiorino, N | 1 |
| Montagna, P | 1 |
| Bagnasco, M | 1 |
| Lenhard, G | 1 |
| Mivsek-Music, E | 1 |
| Perrin-Fayolle, M | 1 |
| Obtulowicz, K | 1 |
| Secchi, A | 1 |
| Horak, F | 1 |
| Berger, UE | 1 |
| Menapace, R | 1 |
| Toth, J | 1 |
| Stübner, PU | 1 |
| Marks, B | 1 |
| Sabbah, A | 1 |
| Marzetto, M | 1 |
| Giede-Tuch, C | 1 |
| Westhoff, M | 1 |
| Zarth, A | 1 |
| Chicharro, JL | 1 |
| Lucía, A | 1 |
| Vaquero, AF | 1 |
| Pérez, M | 1 |
| Pietrzkowicz, M | 1 |
| Grzelewska-Rzymowska, I | 1 |
| Friedlaender, MH | 1 |
| Harris, J | 1 |
| LaVallee, N | 1 |
| Russell, H | 1 |
| Shilstone, J | 1 |
| Giede, C | 1 |
| Metzenauer, P | 1 |
| Duarte, C | 1 |
| Baëhre, M | 1 |
| Gharakhanian, S | 1 |
| Leynadier, F | 1 |
| Spangler, DL | 1 |
| Bensch, G | 1 |
| Berdy, GJ | 1 |
5 reviews available for azelastine and Allergic Conjunctivitis
| Article | Year |
|---|---|
Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Cromolyn S | 2018 |
Multiple action agents and the eye: do they really stabilize mast cells?
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Conjunctivitis, Allergic; Cytokines; Dibenzazep | 2009 |
Ocular allergy treatment comparisons: azelastine and olopatadine.
Topics: Administration, Topical; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Clinical Tri | 2004 |
Pharmacotherapy of allergic eye disease.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Anti-Allergic Agents; Anti-I | 2006 |
[Second generation topical antihistaminics].
Topics: Administration, Topical; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Conjunctivit | 1999 |
16 trials available for azelastine and Allergic Conjunctivitis
| Article | Year |
|---|---|
The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
Topics: Adult; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzoxepins; | 2008 |
Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.
Topics: Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Female; Hi | 2008 |
Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Allergic Agents; Antibiotics, Antineoplastic; | 2003 |
Azelastine eye drops in the treatment of perennial allergic conjunctivitis.
Topics: Adolescent; Adult; Allergens; Conjunctivitis, Allergic; Double-Blind Method; Female; Histamine H1 An | 2003 |
Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.
Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Co | 2003 |
Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti- | 2003 |
Topical azelastine in perennial allergic conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Analysis of Variance; Anti-Allergic Agents; Conjun | 2003 |
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
Topics: Adolescent; Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Method; Drug Adminis | 1997 |
Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Conjunctivitis, Allergic; Dermatitis, Irritant; Doubl | 1997 |
Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study.
Topics: Adult; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Cross-Over Studies; Dose-Response | 1998 |
Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children.
Topics: Child; Child, Preschool; Conjunctivitis, Allergic; Double-Blind Method; Female; Histamine H1 Antagon | 1998 |
Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Conjunctivitis, Allergic; Double-Blind Method; Female; Histamine H1 Antagonists; | 1998 |
Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Topics: Adolescent; Adult; Aged; Allergens; Anti-Allergic Agents; Conjunctiva; Conjunctivitis, Allergic; Dou | 2000 |
Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Conjunctivitis, Allergic; Consumer Product Safety; Do | 2000 |
Treatment of severe seasonal rhinoconjunctivitis by a combination of azelastine nasal spray and eye drops: a double-blind, double-placebo study.
Topics: Administration, Intranasal; Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Meth | 2001 |
Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Topics: Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Dibenzoxepins; Double-Blind Method; Female; H | 2001 |
5 other studies available for azelastine and Allergic Conjunctivitis
| Article | Year |
|---|---|
Eudragit RL100 based microspheres for ocular administration of azelastine hydrochloride.
Topics: Administration, Ophthalmic; Animals; Anti-Allergic Agents; Conjunctivitis, Allergic; Delayed-Action | 2012 |
[Allergodil eye drops in the treatment of allergic conjunctivitis].
Topics: Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Female; Histamine H1 Antagonists; Humans; Mal | 2002 |
[Topical H1 antihistaminics in the therapy of acute conjunctival allergic reactions].
Topics: Acute Disease; Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Conjunctivitis, Allergic; Fe | 2004 |
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
Topics: Animals; Anti-Allergic Agents; Benzimidazoles; Coloring Agents; Conjunctivitis, Allergic; Dibenzoxep | 2008 |
Azelastine does not adversely affect aerobic performance.
Topics: Administration, Intranasal; Adolescent; Adult; Anaerobic Threshold; Anti-Allergic Agents; Conjunctiv | 1998 |